Trial · NCT00384293
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| MK0524A Active Run-In, Pre-randomization | STARTED | MK0524A Active Run-In Period | 937 | |
| MK0524A Active Run-In, Pre-randomization | STARTED | MK0524A, 2 g (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | STARTED | Placebo (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | Entered Active run-in, MK0524A 1 g | MK0524A Active Run-In Period | 937 | |
| MK0524A Active Run-In, Pre-randomization | Entered Active run-in, MK0524A 1 g | MK0524A, 2 g (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | Entered Active run-in, MK0524A 1 g | Placebo (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | MK0524A Dose Increased to 2 g | MK0524A Active Run-In Period | 813 | |
| MK0524A Active Run-In, Pre-randomization | MK0524A Dose Increased to 2 g | MK0524A, 2 g (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | MK0524A Dose Increased to 2 g | Placebo (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | COMPLETED | MK0524A Active Run-In Period | 433 | |
| MK0524A Active Run-In, Pre-randomization | COMPLETED | MK0524A, 2 g (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | COMPLETED | Placebo (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | NOT COMPLETED | MK0524A Active Run-In Period | 504 | |
| MK0524A Active Run-In, Pre-randomization | NOT COMPLETED | MK0524A, 2 g (Postrandomization Period) | 0 | |
| MK0524A Active Run-In, Pre-randomization | NOT COMPLETED | Placebo (Postrandomization Period) | 0 | |
| Post-randomization Period | STARTED | MK0524A Active Run-In Period | 0 | |
| Post-randomization Period | STARTED | MK0524A, 2 g (Postrandomization Period) | 214 | |
| Post-randomization Period | STARTED | Placebo (Postrandomization Period) | 219 | |
| Post-randomization Period | Received ≥1 Dose of MK0524A Study Drug | MK0524A Active Run-In Period | 0 | |
| Post-randomization Period | Received ≥1 Dose of MK0524A Study Drug | MK0524A, 2 g (Postrandomization Period) | 214 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00384293/flow